A Phase III, Randomized, Double-blind, Placebo-controlled, Efficacy, and Safety Study of Balovaptan in Adults with Autism Spectrum Disorder with a 2-year Open-Label Extension
Medication Clinical Trials
Please see attached flyer for further details about this study.
Interested in participating
Please note that recruitment is closed at this time. To learn more about this study, you can also contact our study coordinator, Rianne Hastie Adams at email: email@example.com or telephone: 416-425-6220, x6515.
F. Hoffman-La Roche.